GLP-1 weight loss, side effects linked to genetic variations - Reuters
GLP-1 weight loss, side effects linked to genetic variations Reuters
Coverage by Political Leaning
See how different sides of the spectrum reported this story
Key People
No people linked to this story
Locations
No locations linked to this story
All Coverage
<a href="https://news.google.com/rss/articles/CBMizwFBVV95cUxNTWJ0dEt6SWxYY1gxLWRjRmpuZkp5bUV3SDRjOV9tVUNGanhfTjZtT1ZXZjNkcmFNWjdZNlFHYUJfa01IMWVnR2RTWC1rQXNJSE04V21vR3BUXzJ6R0xUWmVvb2FOMlB2ZG1ZNW01NEU1RkhFZFI4akI1MWl5NGtmaVhPLXRRcmxNd3RBQzcxS0xmUFc5Vm92NUJiR2lLRFJ1QmE1VjJvdEhqYVA1U2E2Qkh4VUZRUkpaMWNiLUFzZmtHS0N0dTNiVmRpNDM2NFU?oc=5" target="_blank">GLP-1 weight loss, side effects linked to genetic variations</a> <font color="#6f6f6f">Reuters</font>
Similar Stories
Related coverage based on topic and tags
Lilly sues six companies over alleged illegal sales of experimental obesity drug retatrutide - reuters.com
Lilly sues six companies over alleged illegal sales of experimental obesity drug retatrutide reuters.com
August 12, 2026 at 10:27 AMPrader-Willi experts flag safety risks linked to Neurocrine's rare disease drug - Reuters
Prader-Willi experts flag safety risks linked to Neurocrine's rare disease drug Reuters
August 12, 2026 at 04:25 PMNovo begins study to find lowest effective dose for Wegovy pill - Reuters
Novo begins study to find lowest effective dose for Wegovy pill Reuters
August 19, 2026 at 03:26 PMNovo CEO says obesity market won't be winner-take-all battle with Lilly - reuters.com
Novo CEO says obesity market won't be winner-take-all battle with Lilly reuters.com
August 13, 2026 at 10:02 AMEyePoint's drug for age-related eye disease fails late-stage trial, shares tank - Reuters
EyePoint's drug for age-related eye disease fails late-stage trial, shares tank Reuters
August 17, 2026 at 03:45 PMNew weight-loss pill approved for use in UK
Foundayo is made by Eli Lilly, the drug firm behind the Mounjaro jab.
August 10, 2026 at 03:25 PM